Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration - Takeaways - MDSpire

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration

  • By

  • Timothy E. Richardson

  • Jonathan Cherry

  • Shrishtee Kandoi

  • Susan K. Rohde

  • Madeline Uretsky

  • Fatima Tuz-Zahra

  • Kevin F. Bieniek

  • Kurt Farrell

  • Marco M. Hefti

  • Michael B. Miller

  • Yorghos Tripodis

  • Thor D. Stein

  • Carolina Maldonado-Díaz

  • Satomi Hiya

  • Thomas G. Beach

  • María M. Corrada

  • Brittany N. Dugger

  • Margaret E. Flanagan

  • Matthew P. Frosch

  • Marla Gearing

  • Lea T. Grinberg

  • Lawrence A. Hansen

  • Debra Hawes

  • Elizabeth Head

  • C. Dirk Keene

  • Julia Kofler

  • Edward B. Lee

  • Peter T. Nelson

  • Derek H. Oakley

  • Richard J. Perrin

  • Robert A. Rissman

  • Shahriar Salamat

  • Julie A. Schneider

  • Geidy E. Serrano

  • Andrew F. Teich

  • Juan C. Troncoso

  • Thomas Wisniewski

  • Randall L. Woltjer

  • John F. Crary

  • Dennis W. Dickson

  • Ann C. McKee

  • Jamie M. Walker

  • May 25, 2026

  • 0 min

Share

  • 1

    Alzheimer disease is the leading cause of cognitive decline in older adults, affecting 7.2 million Americans aged 65 or older.

  • 2

    Neurofibrillary tangles and β-amyloid plaques are key pathological features of Alzheimer disease, with distinct patterns of deposition in the brain.

  • 3

    Cognitive impairment correlates with Alzheimer disease neuropathologic change, but individual outcomes vary significantly.

  • 4

    The study analyzed 61 individuals with Braak stage V to evaluate the impact of p-tau burden on cognitive status amidst neurodegenerative comorbidities.

  • 5

    Immunohistochemical methods were employed to assess p-tau and Aβ in various brain regions to understand their relationship with cognitive decline.

Original Source(s)

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration

  • by Timothy E. Richardson, Jonathan Cherry, Shrishtee Kandoi, Susan K. Rohde, Madeline Uretsky, Fatima Tuz-Zahra, Kevin F. Bieniek, Kurt Farrell, Marco M. Hefti, Michael B. Miller, Yorghos Tripodis, Thor D. Stein, Carolina Maldonado-Díaz, Satomi Hiya, Thomas G. Beach, María M. Corrada, Brittany N. Dugger, Margaret E. Flanagan, Matthew P. Frosch, Marla Gearing, Lea T. Grinberg, Lawrence A. Hansen, Debra Hawes, Elizabeth Head, C. Dirk Keene, Julia Kofler, Edward B. Lee, Peter T. Nelson, Derek H. Oakley, Richard J. Perrin, Robert A. Rissman, Shahriar Salamat, Julie A. Schneider, Geidy E. Serrano, Andrew F. Teich, Juan C. Troncoso, Thomas Wisniewski, Randall L. Woltjer, John F. Crary, Dennis W. Dickson, Ann C. McKee, Jamie M. Walker

  • May 25, 2026

Related Content

Cognitive Trajectories and Subsequent Accelerometer-Measured Movement Behavior in Older Adults

Enrique Diaz, M.D., Joins Baptist Health Miami Neuroscience Institute as a Psychiatrist

Board-certified psychiatrist Enrique Diaz, M.D., has joined Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain & Spine Care.

  • by

  • April 30, 2026

  • 2 min
The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions